Myelodysplastic Syndromes (MDS) clinical trials

57 trials changed in the last 30 days: 3 stopped, 26 with notable changes, 28 with minor changes only.

1. Stopped

   BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple…BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax · Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

   Trial terminated

   Also in this update: Trial sites reduced: 16 → 10 locations; Primary completion date changed from estimate of Feb 1, 2027 to Aug 28, 2026

   Bristol-Myers Squibb·Phase 1· NCT06419634· Registry history of NCT06419634 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Stopped

   Orca-T Following Chemotherapy and Total Marrow and Lymphoid…Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

   Recruitment suspended

   City of Hope Medical Center·Phase 1· NCT06195891· Registry history of NCT06195891 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

3. Stopped

   AIMS · Ascorbate in Myelodysplastic Syndrome

   Recruitment suspended

   Prajwal Dhakal·Phase 2· NCT07283900· Registry history of NCT07283900 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

4. Notable

   Collection of Samples of Bone Marrow Aspiration From…Collection of Samples of Bone Marrow Aspiration From · Myelodysplastic Syndrome

   Primary completion pushed from Dec 31, 2025 to Dec 31, 2027

   Also in this update: Study completion pushed from Mar 1, 2026 to Mar 1, 2028

   Minovia Therapeutics Ltd.·Not specified· NCT06144515· Registry history of NCT06144515 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

5. Notable

   TAK-243 · Relapsed or Refractory Acute Myeloid Leukemia or…TAK-243 · Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

   Primary and study completion pushed from Oct 24, 2026 to Oct 24, 2027

   National Cancer Institute (NCI)·Phase 1· NCT03816319· Registry history of NCT03816319 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

6. Notable

   Graft Versus Host Disease-Reduction Strategies for Donor Blood…Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant · Acute Leukemia or Myelodysplastic Syndrome (MDS)

   Primary completion pushed from Dec 31, 2027 to Dec 31, 2028

   Also in this update: Study completion pushed from Dec 31, 2029 to Dec 31, 2030

   Fred Hutchinson Cancer Center·Phase 2· NCT03970096· Registry history of NCT03970096 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

7. Notable

   Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition…Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

   Primary and study completion pushed from Apr 2026 to Nov 2026

   University of Illinois at Chicago·Phase 2· NCT03121014· Registry history of NCT03121014 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

8. Notable

   Use of Combination Therapy · Persistent Low Level Acute Myeloid…Use of Combination Therapy · Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

   Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2030

   National Cancer Institute (NCI)·Phase 2· NCT05554419· Registry history of NCT05554419 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

9. Notable

   BEXERA · Bexmarilimab + Azacitidine Versus Placebo + Azacitidine…BEXERA · Bexmarilimab + Azacitidine Versus Placebo + Azacitidine · Treatment-naïve Higher-risk Myelodysplastic Syndromes

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Trial sites expanded: 0 → 35 locations

   Faron Pharmaceuticals Ltd·Phase 2· NCT07672769· Registry history of NCT07672769 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

10. Notable

    Eganelisib as Monotherapy and in Combination With Cytarabine in…Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

    Primary endpoint(s) modified

    Also in this update: Primary completion pushed from Jul 15, 2027 to Dec 15, 2027; Enrollment reduced: 125 → 105 participants

    Stelexis BioSciences·Phase 1· NCT06533761· Registry history of NCT06533761 on ClinicalTrials.gov (opens the registry)

    Oct 20, 2026

11. Notable

    Total Marrow and Lymphoid Irradiation in Combination With…Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant · Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

    Primary and study completion pushed from Apr 5, 2029 to Nov 5, 2031

    City of Hope Medical Center·Phase 2· NCT07582172· Registry history of NCT07582172 on ClinicalTrials.gov (opens the registry)

    Oct 8, 2026

12. Notable

    Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before…Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    Primary completion pushed from Sep 2026 to Sep 2027

    Also in this update: Study completion pushed from Mar 2027 to Mar 2028

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Early Phase 1· NCT06398457· Registry history of NCT06398457 on ClinicalTrials.gov (opens the registry)

    Sep 24, 2026

13. Notable

    Ofirnoflast · Very Low- to Intermediate-risk Myelodysplastic…Ofirnoflast · Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

    Primary endpoint(s) modified

    Also in this update: Enrollment increased: 50 → 70 participants; Trial arms changed: 2 → 6

    Halia Therapeutics, Inc.·Phase 2· NCT07738510· Registry history of NCT07738510 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

14. Notable

    Cell Therapies · Relapsed or Refractory Acute Myeloid Leukemia or…Cell Therapies · Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

    Primary endpoint(s) modified

    Also in this update: Sponsor changed: Arcellx, Inc. to Kite, A Gilead Company; Interventions modified

    Kite, A Gilead Company·Phase 1· NCT05457010· Registry history of NCT05457010 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

15. Notable

    CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary…CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

    Primary endpoint(s) modified

    Also in this update: Results posted: Oct 15, 2026

    St. Jude Children's Research Hospital·Phase 2· NCT05656248· Registry history of NCT05656248 on ClinicalTrials.gov (opens the registry)

    Oct 15, 2026

16. Notable

    Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional…Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS

    Primary endpoint(s) modified

    Also in this update: Enrollment increased: 60 → 100 participants; Trial arms changed: 2 → 3

    Washington University School of Medicine·Not applicable· NCT05434598· Registry history of NCT05434598 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

17. Notable

    Omacetaxine + Azacitidine · High Grade MDS

    Primary endpoint(s) modified

    Also in this update: Results posted: Sep 29, 2026; Trial arms changed: 2 → 6

    University of Colorado, Denver·Phase 1/2· NCT03564873· Registry history of NCT03564873 on ClinicalTrials.gov (opens the registry)

    Sep 29, 2026

18. Notable

    AB-CliniMACs · Allogeneic Stem Cell Transplant With Alpha/Beta T…AB-CliniMACs · Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

    Primary endpoint(s) modified

    Also in this update: Phase changed: Phase 2 → not applicable; Results posted: Oct 6, 2026

    Children's Hospital of Philadelphia·Not applicable· NCT02323867· Registry history of NCT02323867 on ClinicalTrials.gov (opens the registry)

    Oct 6, 2026

19. Notable

    Pacritinib · VEXAS Syndrome (PAXIS)

    Enrollment reopened

    Swedish Orphan Biovitrum·Phase 2· NCT06782373· Registry history of NCT06782373 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

20. Notable

    XS-04 · Relapsed or Refractory Hematologic Malignancies

    Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1· NCT06820268· Registry history of NCT06820268 on ClinicalTrials.gov (opens the registry)

    Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.